Linking diabetes and atherosclerosis

References

• Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes23(2), 105–111 (1974).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339(4), 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) study group. J. Am. Coll. Cardiol.21(4), 920–925 (1993).
   PubMedGoogle Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA287(19), 2570–2581 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet352(9123), 213–219 (1998).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA281(14), 1291–1297 (1999).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev.3(2), 463–524 (1987).
   PubMedGoogle Scholar
• Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation102(9), 1014–1019 (2000).
   PubMed Web of Science ®Google Scholar
• Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol.59(8), 750–755 (1987).
   PubMed Web of Science ®Google Scholar
• Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia46(6), 760–765 (2003).
   PubMed Web of Science ®Google Scholar
• Deedwania P, Srikanth S. Diabetes and vascular disease. Expert Rev. Cardiovasc. Ther.6(1), 127–138 (2008).
   PubMedGoogle Scholar
• Sandbaek A, Griffin SJ, Rutten G et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia51(7), 1127–1134 (2008).
   PubMed Web of Science ®Google Scholar
• Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am. J. Cardiol.83(9B), 17F–21F (1999).
   Google Scholar
• Schramm TK, Gislason GH, Kober L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation117(15), 1945–1954 (2008).
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications trial research group. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type-2 diabetes (UKPDS 33). Lancet352(9131), 837–853. (1998).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type-1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type-2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type-2 diabetes. N. Engl. J. Med.358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type-2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type-2 diabetes. N. Engl. J. Med.360(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Renard CB, Kramer F, Johansson F et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest.114(5), 659–668 (2004).
   PubMed Web of Science ®Google Scholar
• Gabbay KH. The sorbitol pathway and the complications of diabetes. N. Engl. J. Med.288(16), 831–836 (1973).
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature404(6779), 787–790 (2000).
   PubMed Web of Science ®Google Scholar
• Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med.43(3), 332–347 (2007).
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab.280(5), E685–E694 (2001).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Davidson J, Hanefeld M et al. Postprandial hyperglycemia and cardiovascular complications of diabetes: an update. Nutr. Metab. Cardiovasc. Dis.16(7), 453–456 (2006).
   PubMed Web of Science ®Google Scholar
• Davi G, Ciabattoni G, Consoli A et al.In vivo formation of 8-iso-prostaglandin f2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation99(2), 224–229 (1999).
   PubMed Web of Science ®Google Scholar
• Mita T, Otsuka A, Azuma K et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun.358(3), 679–685 (2007).
   PubMed Web of Science ®Google Scholar
• Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE study. Diabetologia47(12), 2118–2128 (2004).
   PubMed Web of Science ®Google Scholar
• Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T. Short-term high glucose exposure induces monocyte–endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis193(2), 328–334 (2007).
   PubMed Web of Science ®Google Scholar
• Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem.269(13), 9889–9897 (1994).
   PubMed Web of Science ®Google Scholar
• Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med.318(20), 1315–1321 (1988).
   PubMed Web of Science ®Google Scholar
• Herold K, Moser B, Chen Y et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol.82(2), 204–212 (2007).
   Google Scholar
• Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in Type-2 diabetic patients. Heart85(1), 87–91 (2001).
   PubMedGoogle Scholar
• Lapolla A, Piarulli F, Sartore G et al. Advanced glycation end products and antioxidant status in Type-2 diabetic patients with and without peripheral artery disease. Diabetes Care30(3), 670–676 (2007).
   PubMedGoogle Scholar
• Meerwaldt R, Lutgers HL, Links TP et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care30(1), 107–112 (2007).
   PubMed Web of Science ®Google Scholar
• Kilhovd BK, Juutilainen A, Lehto S et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with Type-2 diabetes: a population-based 18 year follow-up study. Diabetologia50(7), 1409–1417 (2007).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med.1(4), 447–456 (1995).
   PubMed Web of Science ®Google Scholar
• Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes53(7), 1813–1823 (2004).
   PubMed Web of Science ®Google Scholar
• Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res.92(7), 785–792 (2003).
   PubMed Web of Science ®Google Scholar
• Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest.70(2), 138–151 (1994).
   PubMed Web of Science ®Google Scholar
• Menzel EJ, Sobal G, Staudinger A. The role of oxidative stress in the long-term glycation of LDL. Biofactors6(2), 111–124 (1997).
   PubMed Web of Science ®Google Scholar
• Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes44(9), 1093–1098 (1995).
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation114(6), 597–605 (2006).
   PubMed Web of Science ®Google Scholar
• Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res.63(4), 582–592 (2004).
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
   PubMed Web of Science ®Google Scholar
• El-Osta A, Brasacchio D, Yao D et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med.205(10), 2409–2417 (2008).
   PubMed Web of Science ®Google Scholar
• Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl Acad. Sci.105(26), 9047–9052 (2008).
   PubMed Web of Science ®Google Scholar
• Halcox JP, Schenke WH, Zalos G et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation106(6), 653–658 (2002).
   PubMed Web of Science ®Google Scholar
• Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation104(2), 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation105(13), 1567–1572 (2002).
   PubMed Web of Science ®Google Scholar
• Jansson PA. Endothelial dysfunction in insulin resistance and Type-2 diabetes. J. Intern. Med.262(2), 173–183 (2007).
   PubMed Web of Science ®Google Scholar
• Pechanova O, Simko F. The role of nitric oxide in the maintenance of vasoactive balance. Physiol. Res.56(Suppl. 2), S7–S16 (2007).
   Google Scholar
• De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr. Opin. Lipidol.11(1), 9–23 (2000).
   PubMedGoogle Scholar
• Baumgartner-Parzer SM, Wagner L, Pettermann M, Grillari J, Gessl A, Waldhausl W. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes44(11), 1323–1327 (1995).
   PubMed Web of Science ®Google Scholar
• Morigi M, Angioletti S, Imberti B et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J. Clin. Invest.101(9), 1905–1915 (1998).
   PubMed Web of Science ®Google Scholar
• Omi H, Okayama N, Shimizu M et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J. Diabetes Complications16(3), 201–208 (2002).
   PubMed Web of Science ®Google Scholar
• Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, Cosentino F. Selective inhibition of protein kinase Cβ2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation110(1), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen RA. Role of nitric oxide in diabetic complications. Am. J. Ther.12(6), 499–502 (2005).
   PubMedGoogle Scholar
• Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest.87(2), 432–438 (1991).
   PubMed Web of Science ®Google Scholar
• Camici GG, Schiavoni M, Francia P et al. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc. Natl Acad. Sci.104(12), 5217–5222 (2007).
   PubMed Web of Science ®Google Scholar
• Quagliaro L, Piconi L, Assaloni R et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis183(2), 259–267 (2005).
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes54(6), 1615–1625 (2005).
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am. J. Physiol. Endocrinol. Metab.293(1), E337–E346 (2007).
   Web of Science ®Google Scholar
• Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with Type-1 diabetes. Diabetes55(3), 774–779 (2006).
   PubMed Web of Science ®Google Scholar
• Burke AP, Kolodgie FD, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol.24(7), 1266–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Carmody BJ, Arora S, Wakefield MC, Weber M, Fox CJ, Sidawy AN. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J. Vasc. Surg.36(4), 833–838 (2002).
   Google Scholar
• Seki N, Hashimoto N, Sano H et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism52(12), 1558–1563 (2003).
   PubMedGoogle Scholar
• Pfeifle B, Ditschuneit H. The effect of insulin and insulin-like growth factors on cell proliferation of human smooth muscle cells. Artery8(4), 336–341 (1980).
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ299(6708), 1127–1131 (1989).
   PubMed Web of Science ®Google Scholar
• Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ303(6797), 276–282 (1991).
   PubMed Web of Science ®Google Scholar
• Armitage J, Collins R. Need for large scale randomized evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart84(4), 357–360 (2000).
   PubMedGoogle Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes study (UKPDS: 23). BMJ316(7134), 823–828 (1998).
   PubMed Web of Science ®Google Scholar
• Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and Type-2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes52(2), 453–462 (2003).
   PubMed Web of Science ®Google Scholar
• O’Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin. Proc.73(10), 969–976 (1998).
   PubMed Web of Science ®Google Scholar
• Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation94(9), 2171–2176 (1996).
   PubMedGoogle Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet361(9374), 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type-2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet364(9435), 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ332(7550), 1115–1124 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg IJ. Clinical review 124: diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Metab.86(3), 965–971 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang R, Schulze MB, Li T et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with Type-2 diabetes. Diabetes Care27(8), 1991–1997 (2004).
   PubMed Web of Science ®Google Scholar
• El Harchaoui K, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol.49(5), 547–553 (2007).
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in Type-2 diabetes mellitus. Ann. Intern. Med.135(6), 447–459 (2001).
   PubMed Web of Science ®Google Scholar
• Rudel LL, Johnson FL, Sawyer JK, Wilson MS, Parks JS. Dietary polyunsaturated fat modifies low-density lipoproteins and reduces atherosclerosis of nonhuman primates with high and low diet responsiveness. Am. J. Clin. Nutr.62(2), 463S–470S (1995).
   Google Scholar
• Mora S, Szklo M, Otvos JD et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis192(1), 211–217 (2007).
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation113(12), 1556–1563 (2006).
   PubMed Web of Science ®Google Scholar
• Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes53(3), 513–520 (2004).
   PubMed Web of Science ®Google Scholar
• Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation113(21), 2548–2555 (2006).
   PubMed Web of Science ®Google Scholar
• Isoda K, Folco EJ, Shimizu K, Libby P. AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis192(2), 298–304 (2007).
   Google Scholar
• Hoang A, Murphy AJ, Coughlan MT et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia50(8), 1770–1779 (2007).
   Google Scholar
• Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol.26(5), 1144–1149 (2006).
   PubMed Web of Science ®Google Scholar
• Gharavi NM, Gargalovic PS, Chang I et al. High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler. Thromb. Vasc. Biol.27(6), 1346–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Sarov-Blat L, Kiss RS, Haidar B et al. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol.27(5), 1115–1122 (2007).
   Google Scholar
• Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with Type-2 diabetes mellitus. Circulation117(16), 2123–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled Type-2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler. Thromb. Vasc. Biol.19(9), 2226–2233 (1999).
   PubMed Web of Science ®Google Scholar
• Dagher Z, Ruderman N, Tornheim K, Ido Y. The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun.265(1), 112–115 (1999).
   PubMed Web of Science ®Google Scholar
• Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot. Essent. Fatty Acids60(5–6), 411–420 (1999).
   Google Scholar
• Toft I, Bonaa KH, Ingebretsen OC, Nordoy A, Jenssen T. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler. Thromb. Vasc. Biol.17(5), 814–819 (1997).
   Google Scholar
• Rodriguez-Lee M, Bondjers G, Camejo G. Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans. Curr. Opin. Lipidol.18(5), 546–553 (2007).
   Google Scholar
• Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest.116(11), 3015–3025 (2006).
   PubMed Web of Science ®Google Scholar
• Teno S, Uto Y, Nagashima H et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with Type-2 diabetes. Diabetes Care23(9), 1401–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA298(3), 309–316 (2007).
   PubMed Web of Science ®Google Scholar
• Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation109(8), 1022–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Ting HJ, Stice JP, Schaff UY et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-α. Circ. Res.100(3), 381–390 (2007).
   PubMedGoogle Scholar
• Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J. Atheroscler. Thromb.16(1), 6–11 (2009).
   PubMed Web of Science ®Google Scholar
• Johansson F, Kramer F, Barnhart S et al. Type-1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc. Natl Acad. Sci. USA105(6), 2082–2087 (2008).
   Google Scholar
• Nestel PJ, Shige H, Pomeroy S, Cehun M, Chin-Dusting J. Post-prandial remnant lipids impair arterial compliance. J. Am. Coll. Cardiol.37(7), 1929–1935 (2001).
   Google Scholar
• Grossman E, Messerli FH. Hypertension and diabetes. Adv. Cardiol.45, 82–106 (2008).
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type-2 diabetes (UKPDS 36): prospective observational study. BMJ321(7258), 412–419 (2000).
   PubMed Web of Science ®Google Scholar
• Agmon Y, Khandheria BK, Meissner I et al. Independent association of high blood pressure and aortic atherosclerosis: a population-based study. Circulation102(17), 2087–2093 (2000).
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J.116(6 Pt 2), 1713–1724 (1988).
   PubMed Web of Science ®Google Scholar
• Bella JN, Devereux RB, Roman MJ et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am. J. Cardiol.87(11), 1260–1265 (2001).
   PubMed Web of Science ®Google Scholar
• Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care14(3), 220–232 (1991).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. The effect of insulin on renal sodium metabolism. Diabetologia31, 165–171 (1981).
   Google Scholar
• Feldt-Rasmussen B, Mathiesen ER, Deckert T et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type-1 (insulin-dependent) diabetes mellitus. Diabetologia30(8), 610–617 (1987).
   PubMed Web of Science ®Google Scholar
• Luft FC, Miller JZ, Grim CE et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension17, I102–I108 (1991).
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24(4), 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr. Hypertens. Rep.6(3), 215–223 (2004).
   PubMed Web of Science ®Google Scholar
• Ganne S, Arora SK, Dotsenko O, McFarlane SI, Whaley-Connell A. Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr. Diab. Rep.7(3), 208–217 (2007).
   Google Scholar
• Lastra-Gonzalez G, Manrique-Acevedo C, Sowers JR. The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update. Curr. Diab. Rep.8(3), 203–207 (2008).
   Google Scholar
• McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J. Clin. Endocrinol. Metab.88(2), 516–523 (2003).
   PubMed Web of Science ®Google Scholar
• Marcelo LG, Correia KR. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes. Metab.8, 603–610 (2006).
   Google Scholar
• Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann. Intern. Med.113(12), 909–915 (1990).
   PubMed Web of Science ®Google Scholar
• Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J. Clin. Endocrinol. Metab.83(8), 2773–2776 (1998).
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care25(7), 1177–1184 (2002).
   PubMed Web of Science ®Google Scholar
• Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation113(15), 1888–1904 (2006).
   PubMed Web of Science ®Google Scholar
• King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North Am.25(2), 255–270 (1996).
   PubMed Web of Science ®Google Scholar
• Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J. Clin. Invest.105(3), 311–320 (2000).
   PubMed Web of Science ®Google Scholar
• Montagnani M, Golovchenko I, Kim I et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem.277(3), 1794–1799 (2002).
   PubMed Web of Science ®Google Scholar
• Admiraal PJ, Derkx FH, Danser AH, Pieterman H, Schalekamp MA. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension15(1), 44–55 (1990).
   PubMed Web of Science ®Google Scholar
• Danser AH. Local renin–angiotensin systems. Mol. Cell. Biochem.157(1–2), 211–216 (1996).
   Google Scholar
• Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am. J. Cardiol.87(8A), 25C–32C (2001).
   PubMed Web of Science ®Google Scholar
• Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation94(11), 2756–2767 (1996).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation101(12), 1372–1378 (2000).
   PubMed Web of Science ®Google Scholar
• Gross CM, Gerbaulet S, Quensel C et al. Angiotensin II Type-1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res. Cardiol.97(4), 327–333 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet340(8829), 1173–1178 (1992).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3). 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Sechi LA, Griffin CA, Schambelan M. The cardiac renin–angiotensin system in STZ-induced diabetes. Diabetes43(10), 1180–1184 (1994).
   PubMed Web of Science ®Google Scholar
• Candido R, Jandeleit-Dahm KA, Cao Z et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation106(2), 246–253, (2002).
   PubMed Web of Science ®Google Scholar
• Candido R, Allen TJ, Lassila M et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation109(12), 1536–1542 (2004).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation96(10), 3264–3265 (1997).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and end point data. Am. J. Cardiol.88(9A), 1L–20L (2001).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin–angiotensin system and cardiovascular risk. Lancet369(9568), 1208–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am. J. Physiol.274(1 Pt 1), C214–C220 (1998).
   PubMed Web of Science ®Google Scholar
• Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res.90(4), E58–E65 (2002).
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension45(4), 526–529 (2005).
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med.353(10), 999–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Nickenig G, Sachinidis A, Seewald S, Bohm M, Vetter H. Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens. Suppl.15(6), S27–S30 (1997).
   Google Scholar
• Morawietz H, Rueckschloss U, Niemann B et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation100(9), 899–902 (1999).
   PubMed Web of Science ®Google Scholar
• Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc. Res.41(2), 402–417 (1999).
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res.87(5), E1–E9 (2000).
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem.275(43), 33238–33243 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1–7). Hypertension30(3 Pt 2), 535–541 (1997).
   PubMed Web of Science ®Google Scholar
• Turner AJ. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem. Soc. Trans.31(Pt 3), 723–727 (2003).
   PubMed Web of Science ®Google Scholar
• Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc. Med.13(3), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Kostenis E, Milligan G, Christopoulos A et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II Type-1 receptor. Circulation111(14), 1806–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1–7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension37(1), 72–76 (2001).
   PubMed Web of Science ®Google Scholar
• Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension50(6), 1093–1098 (2007).
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol.295(4), H1377–H1384 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J. Am. Soc. Nephrol.16(10), 2976–2984 (2005).
   PubMed Web of Science ®Google Scholar
• Allen TJ, Jandeleit-Dahm KA. Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosis. Curr. Drug Targets Cardiovasc. Haematol. Disord.5(6), 503–512 (2005).
   Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340(2), 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res.91(4), 281–291 (2002).
   PubMed Web of Science ®Google Scholar
• Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci.92(18), 8264–8268 (1995).
   PubMed Web of Science ®Google Scholar
• van Puijvelde GH, Hauer AD, de Vos P et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation114(18), 1968–1976 (2006).
   PubMed Web of Science ®Google Scholar
• van Puijvelde GH, van Es T, van Wanrooij EJ et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(12), 2677–2683 (2007).
   PubMed Web of Science ®Google Scholar
• Steffens S, Burger F, Pelli G et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation114(18), 1977–1984 (2006).
   PubMed Web of Science ®Google Scholar
• Saini A, Liu YJ, Cohen DJ, Ooi BS. Hyperglycemia augments macrophage growth responses to colony-stimulating factor-1. Metabolism45(9), 1125–1129 (1996).
   PubMedGoogle Scholar
• Lamharzi N, Renard CB, Kramer F et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes53(12), 3217–3225 (2004).
   Google Scholar
• Loomans CJ, van Haperen R, Duijs JM et al. Differentiation of bone marrow derived endothelial progenitor cells is shifted into a pro-inflammatory phenotype by hyperglycemia. Mol. Med.15(5–6), 152–159 (2009).
   Google Scholar
• Secchiero P, Candido R, Corallini F et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation114(14), 1522–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Candido R, Toffoli B, Corallini F et al. Human full-length osteoprotegerin (OPG) induces proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res.114(14), 1522–1530 (2009).
   Google Scholar
• Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis184(2), 446–447 (2006).
   PubMed Web of Science ®Google Scholar
• Michowitz Y, Goldstein E, Roth A et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J. Am. Coll. Cardiol.45(7), 1018–1024 (2005).
   PubMed Web of Science ®Google Scholar
• Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun.247(3), 610–615 (1998).
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev.12(9), 1260–1268 (1998).
   PubMed Web of Science ®Google Scholar
• Bennett BJ, Scatena M, Kirk EA et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol.26(9), 2117–2124 (2006).
   PubMed Web of Science ®Google Scholar
• Kavurma MM, Bennett MR. Expression, regulation and function of TRAIL in atherosclerosis. Biochem. Pharmacol.75(7), 1441–1450 (2008).
   PubMed Web of Science ®Google Scholar
• Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab.86(2), 631–637 (2001).
   PubMed Web of Science ®Google Scholar
• Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front. Biosci.13, 135–147 (2008).
   PubMed Web of Science ®Google Scholar
• Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in Type-2 diabetic patients with microvascular complications. Eur. J. Endocrinol.149(1), 39–42 (2003).
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet358(9278), 257–259 (2001).
   PubMed Web of Science ®Google Scholar
• Ostergaard J, Hansen TK, Thiel S, Flyvbjerg A. Complement activation and diabetic vascular complications. Clin. Chim. Acta.361(1–2), 10–19 (2005).
   Google Scholar
• Saraheimo M, Forsblom C, Hansen TK et al. Increased levels of mannan-binding lectin in Type-1 diabetic patients with incipient and overt nephropathy. Diabetologia48(1), 198–202 (2005).
   PubMedGoogle Scholar
• Hansen TK, Tarnow L, Thiel S et al. Association between mannose-binding lectin and vascular complications in Type-1 diabetes. Diabetes53(6), 1570–1576 (2004).
   PubMed Web of Science ®Google Scholar
• Acosta J, Hettinga J, Fluckiger R et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc. Natl Acad. Sci. USA97(10), 5450–5455 (2000).
   PubMed Web of Science ®Google Scholar
• Uesugi N, Sakata N, Nangaku M et al. Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am. J. Kidney Dis.44(2), 224–238 (2004).
   Google Scholar
• Qin X, Goldfine A, Krumrei N et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes53(10), 2653–2661 (2004).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Blackburn G, Brancati FL et al. Reduction in weight and cardiovascular disease risk factors in individuals with Type-2 diabetes: one-year results of the look AHEAD trial. Diabetes Care30(6), 1374–1383 (2007).
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation115(1), 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Kawachi I, Colditz GA, Stampfer MJ et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch. Intern. Med.154(2), 169–175 (1994).
   PubMedGoogle Scholar
• Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD. Cigarette smoking and mortality. MRFIT Research Group. Prev. Med.20(5), 638–654 (1991).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet371(9607), 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care29(6), 1220–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Management of dyslipidemia in adults with diabetes. Diabetes Care23(Suppl. 1), S57–S60 (2000).
   PubMedGoogle Scholar
• Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia49(4), 766–774 (2006).
   PubMed Web of Science ®Google Scholar
• Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res.94(9), 1168–1178 (2004).
   PubMed Web of Science ®Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in Type-2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet357(9260), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch. Intern. Med.166(7), 743–748 (2006).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type-2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension37(4), 1053–1059 (2001).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Reed J. 1999 Clinical advisory treatment of hypertension and diabetes. J. Clin. Hypertens.2(2), 132–133 (2000).
   Google Scholar
• Tight blood pressure control and risk of macrovascular and microvascular complications in Type-2 diabetes: UKPDS 38. UK Prospective Diabetes study group. BMJ317(7160), 703–713 (1998).
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study group. Lancet351(9118), 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trial investigators. N. Engl. J. Med.340(9), 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type-2 diabetes. N. Engl. J. Med.359(15), 1565–1576 (2008).
   PubMed Web of Science ®Google Scholar
• Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention project. Diabetes Care24(12), 2091–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation study investigators. Lancet355(9200), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type-2 diabetes and nephropathy. N. Engl. J. Med.345(12), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type-2 diabetes: UKPDS 39. BMJ317(7160), 713–720. (1998).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type-2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet370(9590), 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• Boner G, Cooper ME, McCarroll K et al. Adverse effects of left ventricular hypertrophy in the reduction of end points in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia48(10), 1980–1987 (2005).
   PubMedGoogle Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Calkin AC, Forbes JM, Smith CM et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler. Thromb. Vasc. Biol.25(9), 1903–1909 (2005).
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med.351(11), 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomized controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for Type-2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet373(9681), 2125–2135 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson SP, Calkin AC. The clot thickens – oxidized lipids and thrombosis. Nat. Med.13(9). 1015–1016 (2007).
   PubMed Web of Science ®Google Scholar
• Bhatt DL. What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J. Am. Coll. Cardiol.52(13), 1060–1061 (2008).
   PubMed Web of Science ®Google Scholar
• Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J. Am. Coll. Cardiol.49(6), 643–656 (2007).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type-2 diabetes. N. Engl. J. Med.348(5), 383–393 (2003).
   PubMed Web of Science ®Google Scholar